Travere Therapeutics Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
497
- Stock Symbol
-
TVTX
- Investments
-
6
- Share Price
-
$50.64
- (As of Friday Closing)
Travere Therapeutics General Information
Description
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Contact Information
Website
www.travere.comCorporate Office
- 3611 Valley Centre Drive
- Suite 300
- San Diego, CA 92130
- United States
Corporate Office
- 3611 Valley Centre Drive
- Suite 300
- San Diego, CA 92130
- United States
Travere Therapeutics Stock Performance
As of 13-Nov-2026, Travere Therapeutics’s stock price is $50.64. Its current market cap is $4.86B with 96M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $50.64 | $51.56 | $22.59 - $68.73 | $4.86B | 96M | 1.81M | -$1.30 |
Travere Therapeutics Financials Summary
As of 30-Sep-2026, Travere Therapeutics has a trailing 12-month revenue of $651M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 5,677,821 | 3,493,957 | 1,641,133 | 446,396 |
| Revenue | 651,034 | 490,728 | 233,175 | 145,238 |
| EBITDA | (110,303) | 9,497 | (283,590) | (348,014) |
| Net Income | (121,507) | (25,546) | (321,545) | (111,399) |
| Total Assets | 848,229 | 605,191 | 594,125 | 788,913 |
| Total Debt | 616,155 | 328,733 | 401,584 | 404,784 |
Travere Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Travere Therapeutics Comparisons
Industry
Financing
Details
Travere Therapeutics Competitors (117)
One of Travere Therapeutics’s 117 competitors is Rhythm Pharmaceuticals, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals | Formerly VC-backed | Boston, MA | ||||
| Regenxbio | Formerly VC-backed | Rockville, MD | ||||
| Harmony Biosciences Holdings | Formerly VC-backed | Plymouth Meeting, PA | ||||
| Abeona Therapeutics | Corporation | Cleveland, OH | ||||
| ACADIA Pharmaceuticals | Formerly VC-backed | San Diego, CA |
Travere Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Travere Therapeutics Patents
Travere Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026207026-A1 | Urinary biomarker analysis reveals rapid intra-renal anti-inflammatory and anti-fibrotic effects of sparsentan in iga nephropathy (igan) | Pending | 25-Mar-2025 | ||
| WO-2026165438-A1 | Sparsentan for the treatment of patients post kidney transplantation with proteinuric iga nephropathy or fsgs | Pending | 31-Jan-2025 | ||
| AU-2024343419-A1 | Sparsentan for treating immunoglobulin a nephropathy (igan) | Pending | 20-Sep-2023 | ||
| EP-4780449-A1 | Sparsentan for treating immunoglobulin a nephropathy (igan) | Pending | 20-Sep-2023 | ||
| WO-2025064688-A1 | Sparsentan for treating immunoglobulin a nephropathy (igan) | Inactive | 20-Sep-2023 | A61K31/422 |
Travere Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Travere Therapeutics Investments & Acquisitions (6)
Travere Therapeutics’s most recent deal was a Merger/Acquisition with Orphan Technologies for . The deal was made on 12-Nov-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Orphan Technologies | 12-Nov-2020 | Merger/Acquisition | Drug Discovery | ||
| Perlara | 01-Apr-2015 | Early Stage VC | Drug Discovery | ||
| Asklepion Pharmaceuticals | 18-Mar-2015 | Corporate | Other Healthcare Services | ||
| Manchester Pharmaceuticals | 26-Mar-2014 | Merger/Acquisition | Pharmaceuticals | ||
| Kyalin Biosciences | 23-Dec-2013 | Merger/Acquisition | Drug Discovery |
Travere Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
31.44 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Travere Therapeutics FAQs
-
When was Travere Therapeutics founded?
Travere Therapeutics was founded in 2011.
-
Where is Travere Therapeutics headquartered?
Travere Therapeutics is headquartered in San Diego, CA.
-
What is the size of Travere Therapeutics?
Travere Therapeutics has 497 total employees.
-
What industry is Travere Therapeutics in?
Travere Therapeutics’s primary industry is Pharmaceuticals.
-
Is Travere Therapeutics a private or public company?
Travere Therapeutics is a Public company.
-
What is Travere Therapeutics’s stock symbol?
The ticker symbol for Travere Therapeutics is TVTX.
-
What is the current stock price of Travere Therapeutics?
As of 13-Nov-2026 the stock price of Travere Therapeutics is $50.64.
-
What is the current market cap of Travere Therapeutics?
The current market capitalization of Travere Therapeutics is $4.86B.
-
What is Travere Therapeutics’s current revenue?
The trailing twelve month revenue for Travere Therapeutics is $651M.
-
Who are Travere Therapeutics’s competitors?
Rhythm Pharmaceuticals, Regenxbio, Harmony Biosciences Holdings, Abeona Therapeutics, and ACADIA Pharmaceuticals are some of the 117 competitors of Travere Therapeutics.
-
What is Travere Therapeutics’s annual earnings per share (EPS)?
Travere Therapeutics’s EPS for 12 months was -$1.30.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
